IL2 and graft versus host disease: Clinical trials in graft versus host disease (GVHD) and vasculitis using low-dose IL-2 as a stand-alone therapy for inflammatory and autoimmune conditions have already demonstrated increased Treg survival in these conditions and reduced disease activity [95–98].